TECLens: $9.3 Million (Series A) Raised For Advancing Non-Invasive Refractive Technology
Summary
And TECLens proprietary Quantitative Corneal Cross-Linking (qCXL) is designed to deliver a pre-calculated pattern and dose of UV light based on a computational biomechanics model of each patients eye. The companys proprietary CXLens device comfortably offers UV light and treatment progression in real-time with an onboard ultrasound sensor to ensure adherence to the pre-plan, enhancing precision.The CXLens device, designed for use in the exam room, has been demonstrated in the eyes with keratoconus. This collective backing of our investors is a powerful endorsement of both our quantitative corneal cross-linking technology and our mission to deliver a non-invasive and cost-effective refractive treatment for millions of people with vision disorders. Were honored by their support and view this as a strong validation of our innovative approach to addressing both refractive and therapeutic unmet needs in eye care.The TECLens qCXL technology has tremendous potential to improve access to care for some of the worlds most complex vision correction needs, including presbyopia, keratoconus, low-order myopia, hyperopia, and astigmatism. Dr. Roy Chuck, Chairman, Department of Ophthalmology, Montefiore Einstein and a pioneer of the foundational technologies behind TECLens